GSK3B and schizophrenia: Another study showed increased inhibitory phosphorylation of GSK3β and β-catenin, but no significant changes in mRNA or protein levels in PFC and VTA of rats treated with MK-801, an NMDA glutamate-receptor antagonist which induces schizophrenia-like behaviours [229].